These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 5553940)
1. [Transmethylating activity in vitro in patients with parkinsonism before and after treatment with L-dopa]. Carella A; Valenti P; Buscaino GA Acta Neurol (Napoli); 1971; 26(1):41-5. PubMed ID: 5553940 [No Abstract] [Full Text] [Related]
2. L-Dopa and Parkinsonism. Calne DB; Sandler M Nature; 1970 Apr; 226(5240):21-4. PubMed ID: 4907560 [No Abstract] [Full Text] [Related]
3. The pharmacology of parkinsonism (a review). Klawans HL Dis Nerv Syst; 1968 Dec; 29(12):805-16. PubMed ID: 4388368 [No Abstract] [Full Text] [Related]
4. [Symposium: metabolism in neurological disorders. 1. Parkinsonism. 1-(2). Dopamin metabolism in urine and brain of patients with parkinsonism, with special reference to vitamin B 6 and L-DOPA-treatment]. Kuzuya F; Wakita T; Kawahara H Nihon Naika Gakkai Zasshi; 1972 Sep; 61(9):1131-5. PubMed ID: 4674039 [No Abstract] [Full Text] [Related]
5. [Therapy of parkinsonism using L-dopa. I]. Glass J Z Arztl Fortbild (Jena); 1972 Dec; 66(23):1195-9. PubMed ID: 4652156 [No Abstract] [Full Text] [Related]
6. Tyrosine hydroxylase deficiency. A unifying concept of Parkinsonism. Martin WE Lancet; 1971 May; 1(7708):1050-1. PubMed ID: 4102972 [No Abstract] [Full Text] [Related]
7. The effect of L-dopa on monoamine metabolites in Parkinson's disease. van Woert MH; Bowers MB Experientia; 1970; 26(2):161-3. PubMed ID: 5308739 [No Abstract] [Full Text] [Related]
8. L-dopa metabolism in man (with special reference to parkinsonism). Sandler M Sci Basis Med Annu Rev; 1972; ():161-73. PubMed ID: 4564341 [No Abstract] [Full Text] [Related]
9. [Experiences in the treatment of Parkinsonism with L-dopa. 3. Laboratory findings in patients treated with L-dopa]. Bergamini L; Bonzanino A; Bignolio F; Fabiani A; Fariello R; Mombelli AM; Mutani R; Pisani W; Postir A; Riccio A; Sabbatini F; Sandigliano G; Schiffer D Riv Patol Nerv Ment; 1970 Feb; 91(1):10-6. PubMed ID: 5524931 [No Abstract] [Full Text] [Related]
10. L-dopa therapy in parkinsonism: mechanism of action. Sandler M Psychiatr Neurol Neurochir; 1971; 74(4):331-3. PubMed ID: 5146239 [No Abstract] [Full Text] [Related]
11. [Implications of the formulation of m-tyrosine from DOPA for Parkinsonism]. Stoof JC; Koetsier JC Ned Tijdschr Geneeskd; 1974 Jun; 118(23):900. PubMed ID: 4839449 [No Abstract] [Full Text] [Related]
12. [Dopamine and parkinsonism]. Siegfried J Schweiz Med Wochenschr; 1968 Mar; 98(11):429-31. PubMed ID: 5700507 [No Abstract] [Full Text] [Related]
13. [On the treatment of Parkinson's syndrome with monoamine oxidase inhibitors alone and in combination with L-dopa]. Gerstenbrand F; Prosenz P Praxis; 1965 Nov; 54(46):1373-7. PubMed ID: 5899418 [No Abstract] [Full Text] [Related]
14. [The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations]. Morselli PL; Rizzo M; Tognoni G Recenti Prog Med; 1970 Feb; 48(2):97-124. PubMed ID: 5467589 [No Abstract] [Full Text] [Related]
15. [L-DOPA therapy of parkinsonism]. Refsum S Nord Med; 1969 May; 81(18):570-1. PubMed ID: 5768311 [No Abstract] [Full Text] [Related]
16. The metabolism of orally administered L-dopa in Parkinson patients. Cote LJ; Cohen G; Yahr MD Trans Am Neurol Assoc; 1971; 96():222-3. PubMed ID: 5159086 [No Abstract] [Full Text] [Related]
17. Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man. Sandler M; Goodwin BL; Ruthven CR Nature; 1971 Feb; 229(5284):414-5. PubMed ID: 4926994 [No Abstract] [Full Text] [Related]
19. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines]. Uono M; Tanabe H; Yano Y; Nakao K No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082 [No Abstract] [Full Text] [Related]